ReviewRomanian journal of ophthalmology
Optical Coherence Tomography Angiography in Age-Related Macular Degeneration.
Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To review and synthesize current evidence regarding the importance of optical coherence tomography angiography (OCTA) in the assessment of choriocapillaris alterations and macular neovascularization (MNV) across the spectrum of age-related macular degeneration (AMD), focusing on disease progression and clinical implications. Methods: Selective review of the specialized literature, concentrating on both qualitative and quantitative OCTA analyses of the retinal and choroidal microvasculature in AMD. We focused on measures related to choriocapillaris flow deficits, the morphology and maturity of MNV, and their associations with structural changes like drusen, geographic atrophy, and exudative conditions. The review included findings from both spectral-domain and swept-source OCTA systems. Results: OCTA enables non-invasive, depth-resolved visualization of choriocapillaris and MNV alterations throughout the progression of AMD. In the early and intermediate stages of AMD, localized choriocapillaris flow deficits are often observed beneath drusen and around lesion areas. In more advanced stages, there is significant choriocapillaris damage, especially near geographic atrophy and macular neovascularization. Quantitative OCTA biomarkers, such as density and flow deficit percentage, show strong correlations with disease stage, progression risk, and treatment response. Additionally, the maturity patterns of MNV identified through OCTA seem to affect the integrity of the surrounding choriocapillaris and the dynamics of atrophy. Discussion: The reviewed studies support a close relationship between choriocapillaris dysfunction, the development of macular neovascularization, and the progression of AMD. These findings reinforce the concept that vascular alterations play a central role throughout the disease spectrum and highlight the potential of OCTA to provide biomarkers that may improve prognostic assessment and treatment monitoring. However, further standardization of imaging protocols and quantitative analysis methods is needed before these biomarkers can be fully integrated into routine clinical practice. Conclusions: OCTA has become a crucial imaging tool for understanding microvascular changes in AMD. The quantitative evaluation of the choriocapillaris and detailed analysis of MNV morphology offer important insights into disease mechanisms, progression risk, and treatment monitoring. Incorporating OCTA-derived biomarkers into routine clinical practice could improve personalized management strategies for patients across the spectrum of AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.